Diabetes treatment is constantly progressing, with new therapeutic options emerging to improve patient outcomes. Recent investigations have focused on GLP-1 and GIP receptor agonists, a group of drugs that mimic the actions of naturally occurring hormones involved in bloodlevel regulation. These novel agents demonstrate significant efficacy in cont

Retaglutide and tirzepatide represent innovative class of medications known as dual GLP-1 and GIP agonists. These agents influence both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that perform a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones